[1] Huclier-Markai S, Alliot C, Varmenot N, Cutler CS, Barbet J. “Alpha-emitters for immuno- therapy: a review of recent developments from chemistry to clinics” Curr Top Med Chem. 2012;12:2642–2654.
[2] Kim YS, Brechbiel MW. “An overview of targeted alpha therapy” Tumor Biol. 2012;33:573– 590.
[3] Kozempel J, Vlk M, Malkova E, et al. “Prospective carriers of 223Ra for targeted alpha particle therapy” J Radioanal Nucl Chem. 2015;304:443– 447.
[4] Imam SK. “Advancements in cancer therapy with alpha-emitters: a review” Int J Radiat Oncol Biol Phys. 2001;51:271–278.
[5] Sartor O, Maalouf BN, Hauck CR, Macklis RM. “Targeted use of alpha particles: current status in cancer therapeutics” J Nucl Med Radiat Ther. 2012;3:1000136.
[6] Mulford DA, Scheinberg DA, Jurcic JG. “The promise of targeted alpha- particle therapy” J Nucl Med. 2005;46:199S–204S.
[7] Feng Y, Zalutsky MR. “Production, purification and availability of 211At: near term steps toward global access” Nucl Med Biol. 2021;100:12–23.
[8] Liu Y, Watabe T, Kaneda-Nakashima K, Shirakami Y, Ooe K, Toyoshima A, Shimosegawa E, Wang Y, Haba H, Nakano T, Shinohara A, Hatazawa J. “Comparison of the Therapeutic Effects of [211At]NaAt and [131I]NaI in an NIS-expressing Thyroid Cancer Mouse Model” 26 July 2021, PREPRINT (Version 1) available at Research Square.
[9] Watabe T, Kaneda-Nakashima K, Ooe K, Liu Y, Kurimoto K, Murai T, Shidahara Y, Okuma K, Takeuchi M, Nishide M, Toyoshima A, Shinohara A, Shirakami Y. “Extended single-dose toxicity study of [(211)At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer” Ann Nucl Med. 2021;35:702–718.
[10] Watabe T, Hosono M, Kinuya S, Yamada T, Yanagida S, Namba M, Nakamura Y. “Manual on the proper use of sodium astatide ([(211)At]NaAt) injections in clinical trials for targeted alpha therapy (1st edition)” Ann Nucl Med. 2021;35:753–766.
[11] Watabe T, Kaneda-Nakashima K, Liu Y, et al. “Enhancement of 211At uptake via the sodium iodide symporter by the addition of ascorbic acid in targeted a-therapy of thyroid cancer” J Nucl Med. 2019;60:1301–1307.
[12] Johnson EL, Turkington TG, Jaszczak RJ, et al. “Quantitation of 211At in Small Volumes for Evaluation of Targeted Radiotherapy in Animal Models” Nuci Med Biol. 1995;22:45–54.
[13] Ito T, Matsusaka Y, Onoguchi M, Ichikawa H, Kouda K, Shibutani T, Shishido M, Sato K. “Experimental evaluation of the GE NM/CT 870 CZT clinical SPECT system equipped with WEHR and MEHRS collimator” J. Appl. Clin. Med. Phys. 2020;22:165–177.
[14] Thibault F, Bailly M, Le Rouzic G, Metrard G. “Clinical evaluation of General Electric new Swiftscan solution in bone scintigraphy on NaI-camera: A head to head comparison with Siemens Symbia” PLoS One. 2019; 14(9): e0222490.
[15] Tanaka E, Hiramoto T, Nohara N. “Scintillation cameras based on new position arithmetics”. J. Nucl. Med. 1970;11 (9): 542–547.
[16] Yamamoto S. “Resolution improvement using a fiber optic plate for a small field-of- view NaI(Tl) gamma camera” IEEE Trans. Nucl. Sci. 2006; 53 (1): 49–53.
[17] Nakanishi K, Yamamoto S, Kataoka J. “Performance comparison of finely pixelated LYSO- and GAGG-based Si-PM gamma cameras for high-resolution SPECT” Nucl. Instrum. Methods Phys. Res. A 2017;872:107-111.
[18] Moses WW, Bizarri GA, Williams RT, et al. “The origins of scintillator non-proportionality” IEEE Trans Nucl Sci. 2012;59:2038–2044.
[19] Khodyuk IV, Dorenbos P. “Trends and patterns of scintillator nonproportionality, IEEE Trans. Nucl. Sci. 2012; 59(6): 3320-3331.
[20] Yamamoto S, Kamada K, Yoshikawa A. “Use of YAP(Ce) in the development of high spatial resolution radiation imaging detectors”, Radiat. Meas. 2018; 119: 184-191.
[21] Moszynski M. “Energy resolution and non-proportionality of scintillation detectors—new observations” Radiat. Meas. 2010; 45: 372-376.
[22] Stefaniuk I, Rogalska I, Suchocki A, Berkowski M, Cieniek B, Potera P. “Electron paramagnetic resonance studies of manganese and cobalt ions in YAlO3 crystals” Opt. Appl. XLIV 2014;1: 113–121.
[23] Donnald SB, Williams R, Melcher CL, Meng F, Hayward JP. “Correlation of nonproportionality and scintillation properties with cerium concentration in YAIO3:Ce” IEEE Trans. Nucl. Sci. 2018; 65(5): 1218-1225.
[24] Dorenbos P, Haas JTM, Eijk CWE. “Nonproportionality in the scintillation response and the energy resolution obtainable with scintillation crystals,” IEEE Trans. Nucl. Sci. 1995;42:2190- 2202.
[25] Valentine JD, Rooney BD, Li J. “The light yield nonproportionality component of scintillator energy resolution” IEEE Trans. Nucl. Sci. 1998; 45: 512-517.
[26] Baccaro S, Blazek K, De Notaristefani F, Maly P, Mares JA, Pani R, Pellegrini R, Soluri A. “Scintillation properties of YAP:Ce”. Nucl. Instrum. Methods Phys. Res. A 1995;361:209–215.
[27] Guerra AD, Domenico GD, Scandola M, Zavattini G. “High spatial resolution small animal YAP- PET”. Nucl. Instrum. Methods Phys. Res. A 1998;409:537–541.
[28] Vilardi I, Braem A, Chesi E, et al. “Optimization of the effective light attenuation length of YAP: Ce and LYSO: Ce crystals for a novel geometrical PET concept” Nucl. Instrum. Methods Phys. Res. A 2006;564:506–514.
[29] Kapusta M, Pawelke J, Moszyhski M. “Comparison of YAP and BGO for high- resolution PET detectors” Nucl. Instr. Meth. Phys. Res A 1998;404:413–417.
[30] Yamamoto S, Honda M, Oohashi T, Shimizu K, Senda M. “Development of a brain PET system, PET-Hat: a wearable PET system for brain research” IEEE trans. Nucl. Sci. 2011;58 (3):668– 673.
[31] Nakanishi K, Hirano Y, Yamamoto S. “Comparison of noise equivalent count rates (NECRs) for the PET systems with different ring diameter and electronics” IEEE trans. Radi. Plas. Med. Sci. 2019;3 (3): 371–376.
[32] Moszynski M, Kapusta M, Wolski D, Klamra W, Cederwall B. “Properties of the YAP:Ce scintillator” Nucl. Instrum. Methods A 1998;404 (1):157–165.
[33] Moretti F, Hovhannesyan K, Derdzyan M, et al., “Consequences of Ca codoping in YAlO3:Ce single crystals” ChemPhysChem 2017;18:493–499.
[34] Kumar V, Luo Z. “A review on X-ray excited emission decay dynamics in inorganic scintillator materials” Photonics 2021;8 (71): 1–27.
[35] Turkington TG, Zalutsky MR, Jaszczak RJ, Garg PK, Vaidyanathan G, Coleman RE. “Measuring astatine-211 distributions with SPECT” Phys Med Biol. 1993;38:1121–1130.
[36] Yamamoto S, Watabe H, Kanai Y, Shimosegawa E, Hatazawa J. “Development of a pixelated GSO gamma camera system with tungsten parallel hole collimator for single photon imaging” Med Phys. 2012;39:581–588.
[37] Kasal B, Sharp PF. “Gamma camera spatial resolution as measured by the bar phantom” Phys Med Biol. 1985;30(3):263–266.
[38] Willhauck MJ, Samani BR, Wolf I, et al. “The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer” Eur J Nucl Med Mol Imaging 2008;35:1272–1281.
[39] Portulano C, Paroder-Belenitsky M, Carrasco N. “The Na+/I- symporter (NIS): mechanism and medical impact”. Endocr Rev 2014;35:106-149.
[40] Flux GD. “Imaging and dosimetry for radium-223: the potential for personalized treatment” Br J Radiol. 2017;90:20160748.
[41] Scuffham JW, Pani S, Seller P, et al. “Imaging of Ra-223 with a small- pixel CdTe detector” J Instrum. 2015;10:C01029.